Editorials

Trials of autologous bone marrow stem cells for heart disease

BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g2750 (Published 29 April 2014) Cite this as: BMJ 2014;348:g2750
  1. Nick Freemantle, professor of clinical epidemiology and biostatistics ,
  2. Greta Rait, senior lecturer
  1. 1Priment Clinical Trials Unit, Research Department of Primary Care and Population Health, UCL Medical School, London NW3 2PF, UK
  1. Correspondence to: N Freemantle nicholas.freemantle{at}ucl.ac.uk

A disappointing research effort characterised by errors, inflated effect sizes, and lost opportunity

The report by Nowbar and colleagues (doi:10.1136/bmj.g2688) on the relation between the number of discrepancies observed in clinical trials of autologous bone marrow stem cells for ischaemic heart disease and ejection fraction includes shambolic and poorly conducted research that reflects poorly on every part of the research process.1 On average, trials with many errors show improved ejection fraction, while trials with no errors find no benefit. How should we react to this finding and what lessons can we learn? In An Essay on Criticism, Alexander Pope stated that “to err is human,” but surely there is no place for errors in development of evidence that will inform treatment decisions?2

Errors range from the unfortunate typo to poor design, conduct, analysis, and reporting. Many of the errors described by the authors could be explained and are perhaps less harmful than Nowbar and colleagues imply. There are many descriptions of “impossible” percentages in their paper.1 The authors are quite correct, for example, to say that 65% of 42 participants does not give an integer result, but 65% of 40 participants does and the trialists might simply be correctly accounting for missing data in their …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe